0001209191-20-051037.txt : 20200917
0001209191-20-051037.hdr.sgml : 20200917
20200917191330
ACCESSION NUMBER: 0001209191-20-051037
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200915
FILED AS OF DATE: 20200917
DATE AS OF CHANGE: 20200917
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Williams Kristen Marie
CENTRAL INDEX KEY: 0001296965
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35060
FILM NUMBER: 201182326
MAIL ADDRESS:
STREET 1: C/O PACIRA PHARMACEUTICALS, INC.
STREET 2: 5 SYLVAN WAY, SUITE 300
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
FORMER NAME:
FORMER CONFORMED NAME: Dunker Kristen Marie
DATE OF NAME CHANGE: 20040712
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Pacira BioSciences, Inc.
CENTRAL INDEX KEY: 0001396814
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 510619477
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5 SYLVAN WAY
STREET 2: SUITE 300
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
BUSINESS PHONE: 973-254-3560
MAIL ADDRESS:
STREET 1: 5 SYLVAN WAY
STREET 2: SUITE 300
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
FORMER COMPANY:
FORMER CONFORMED NAME: Pacira Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20101029
FORMER COMPANY:
FORMER CONFORMED NAME: PACIRA INC
DATE OF NAME CHANGE: 20080318
FORMER COMPANY:
FORMER CONFORMED NAME: Blue Acquisition Corp
DATE OF NAME CHANGE: 20070418
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-09-15
0
0001396814
Pacira BioSciences, Inc.
PCRX
0001296965
Williams Kristen Marie
C/O PACIRA BIOSCIENCES, INC.
5 SYLVAN WAY, SUITE 300
PARSIPPANY
NJ
07054
0
1
0
0
Chief Administrative Officer
Common Stock
2020-09-15
4
M
0
5832
40.34
A
30719
D
Common Stock
2020-09-15
4
M
0
5832
32.35
A
36551
D
Common Stock
2020-09-15
4
M
0
5499
44.20
A
42050
D
Common Stock
2020-09-15
4
M
0
7874
38.35
A
49924
D
Common Stock
2020-09-15
4
M
0
2816
43.54
A
52740
D
Common Stock
2020-09-15
4
S
0
14622
59.01
D
38118
D
Common Stock
2020-09-15
4
S
0
13231
59.80
D
24887
D
Common Stock
2020-09-16
4
M
0
5832
40.34
A
30719
D
Common Stock
2020-09-16
4
M
0
5832
32.35
A
36551
D
Common Stock
2020-09-16
4
M
0
5499
44.20
A
42050
D
Common Stock
2020-09-16
4
M
0
7874
38.35
A
49924
D
Common Stock
2020-09-16
4
M
0
2816
43.54
A
52740
D
Common Stock
2020-09-16
4
S
0
6609
59.54
D
46131
D
Common Stock
2020-09-16
4
S
0
21244
60.33
D
24887
D
Common Stock
2020-09-17
4
M
0
5836
40.34
A
30723
D
Common Stock
2020-09-17
4
M
0
5836
32.35
A
36559
D
Common Stock
2020-09-17
4
M
0
5502
44.20
A
42061
D
Common Stock
2020-09-17
4
M
0
7878
38.35
A
49939
D
Common Stock
2020-09-17
4
M
0
2819
43.54
A
52758
D
Common Stock
2020-09-17
4
S
0
24671
59.77
D
28087
D
Common Stock
2020-09-17
4
S
0
3200
60.22
D
24887
D
Stock Option (Right to Buy)
40.34
2020-09-15
4
M
0
5832
0.00
D
2026-06-15
Common Stock
5832
11668
D
Stock Option (Right to Buy)
32.35
2020-09-15
4
M
0
5832
0.00
D
2026-12-07
Common Stock
5832
14168
D
Stock Option (Right to Buy)
44.20
2020-09-15
4
M
0
5499
0.00
D
2027-06-14
Common Stock
5499
16501
D
Stock Option (Right to Buy)
38.35
2020-09-15
4
M
0
7874
0.00
D
2028-06-13
Common Stock
7874
39376
D
Stock Option (Right to Buy)
43.54
2020-09-15
4
M
0
2816
0.00
D
2029-06-05
Common Stock
2816
30984
D
Stock Option (Right to Buy)
40.34
2020-09-16
4
M
0
5832
0.00
D
2026-06-15
Common Stock
5832
5836
D
Stock Option (Right to Buy)
32.35
2020-09-16
4
M
0
5832
0.00
D
2026-12-07
Common Stock
5832
8336
D
Stock Option (Right to Buy)
44.20
2020-09-16
4
M
0
5499
0.00
D
2027-06-14
Common Stock
5499
11002
D
Stock Option (Right to Buy)
38.35
2020-09-16
4
M
0
7874
0.00
D
2028-06-13
Common Stock
7874
31502
D
Stock Option (Right to Buy)
43.54
2020-09-16
4
M
0
2816
0.00
D
2029-06-05
Common Stock
2816
28168
D
Stock Option (Right to Buy)
40.34
2020-09-17
4
M
0
5836
0.00
D
2026-06-15
Common Stock
5836
0
D
Stock Option (Right to Buy)
32.35
2020-09-17
4
M
0
5836
0.00
D
2026-12-07
Common Stock
5836
2500
D
Stock Option (Right to Buy)
44.20
2020-09-17
4
M
0
5502
0.00
D
2027-06-14
Common Stock
5502
5500
D
Stock Option (Right to Buy)
38.35
2020-09-17
4
M
0
7878
0.00
D
2028-06-13
Common Stock
7878
23624
D
Stock Option (Right to Buy)
43.54
2020-09-17
4
M
0
2819
0.00
D
2029-06-05
Common Stock
2819
25349
D
The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.455 to $59.445, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 7.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.455 to $60.100, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.990 to $59.980, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.005 to $60.915, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.130 to $60.120, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.130 to $60.370, inclusive.
The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date.
The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.
/s/ Kristen Williams
2020-09-17